AstraZeneca Signs Global License for Ingenuity's IPA Software | GenomeWeb
NEW YORK (GenomeWeb News) - Ingenuity Systems today said that AstraZeneca has signed a global licensing agreement for its IPA pathway analysis platform.
Adriano Henney, director of discovery enabling capabilities and sciences at AstraZeneca, said in a statement that the company opted for IPA after testing several platforms across seven AstraZeneca sites in three countries for the past year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.